Drug details

Tegsedi (inotersen injection)

type of Rheumatologics Antisense Oligonucleotides

Tegsedi (inotersen) is a transthyretin-directed antisense oligonucleotide indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

This drug may have the following side effects:
  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • loss of appetite,
  • dark urine,
  • vomiting,
  • easy bruising,
  • shortness of breath,
  • weight loss,
  • yellowing of the skin or eyes (jaundice),
  • chest pain,
  • severe headache,
  • back pain,
  • flu-like symptoms,
  • muscle weakness,
  • swelling in your hands or feet,
  • sudden numbness or weakness (especially on one side of the body),
  • slurred speech,
  • problems with vision or balance,
  • coughing up blood,
  • vomit that looks like coffee grounds,
  • puffy eyes,
  • drooping eyelids,
  • neck stiffness,
  • purple or red spots under your skin,
  • pink or brown urine,
  • black or bloody stools,
  • heavy menstrual bleeding,
  • muscle or joint pain, and
  • unusual bleeding (nose, gums, or a cut),
  • bleeding in the whites of your eyes,
  • stomach pain (upper stomach right side),
  • warmth or chills,
  • redness on the palms of hands,
  • uncontrolled muscle movements
The following drugs are related to Tegsedi, either as a replacement or used together:
  • Alkeran (melphalan)
  • Alkeran Injection (melphalan hcl injection)
  • Amvuttra (vutrisiran injection)
  • Cytoxan (cyclophosphamide)
  • Empliciti (elotuzumab for injection)
  • Revlimid (lenalidomide)
  • Onpattro (patisiran lipid complex injection)
  • Pomalyst (pomalidomide capsules)